{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:49:54Z","timestamp":1791578994895,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Amgen Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07302-8","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:25:48Z","timestamp":1791458748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"105","author":[{"given":"Karin","family":"Potthoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyck von der","family":"Heyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Losem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Nusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Sch\u00f6ttker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wilop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Hanselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Serrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Koszinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Knauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"5","key":"7302_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487\u2013497","journal-title":"N Engl J Med"},{"issue":"5","key":"7302_CR2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/bcp.15147","volume":"88","author":"R Lasala","year":"2022","unstructured":"Lasala R, Santoleri F (2022) Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature. Br J Clin Pharmacol 88(5):1999\u20132018","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"7302_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.111.171074","volume":"58","author":"HAW van Onzenoort","year":"2011","unstructured":"van Onzenoort HAW, Menger FE, Neef C et al (2011) Participation in a clinical trial enhances adherence and persistence to treatment. Hypertension 58(4):573\u2013578","journal-title":"Hypertension"},{"issue":"9","key":"7302_CR4","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.3390\/ijerph18094872","volume":"18","author":"E Menditto","year":"2021","unstructured":"Menditto E, Cahir C, Malo S et al (2021) Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health 18(9):4872","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"7302_CR5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/bcp.14075","volume":"85","author":"CA Walsh","year":"2019","unstructured":"Walsh CA, Cahir C, Tecklenborg S et al (2019) The association between medication non-adherence and adverse health outcomes in ageing populations: A systematic review and meta-analysis. Br J Clin Pharmacol 85(11):2464\u20132478","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"7302_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","volume":"166","author":"PM Ho","year":"2006","unstructured":"Ho PM, Rumsfeld JS, Masoudi FA et al (2006) Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166(17):1836\u20131841","journal-title":"Arch Intern Med"},{"issue":"2","key":"7302_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jama.297.2.177","volume":"297","author":"JN Rasmussen","year":"2007","unstructured":"Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2):177\u2013186","journal-title":"JAMA"},{"issue":"2","key":"7302_CR8","doi-asserted-by":"publisher","first-page":"e87027","DOI":"10.1371\/journal.pone.0087027","volume":"9","author":"K-P Hsieh","year":"2014","unstructured":"Hsieh K-P, Chen L-C, Cheung K-L et al (2014) Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women\u2013an Asian population-based study. PLoS ONE 9(2):e87027","journal-title":"PLoS ONE"},{"issue":"10","key":"7302_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.clml.2022.05.003","volume":"22","author":"AY Naser","year":"2022","unstructured":"Naser AY, Ofori-Asenso R, Awawdeh SA et al (2022) Real world adherence to and persistence with oral oncolytics in multiple myeloma: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 22(10):760\u2013773","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"7302_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M et al (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175(1):66\u201376","journal-title":"Br J Haematol"},{"issue":"11","key":"7302_CR11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R et al (2023) Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 389(11):1009\u20131022","journal-title":"N Engl J Med"},{"issue":"6","key":"7302_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cancers16061166","volume":"16","author":"MA Hartley-Brown","year":"2024","unstructured":"Hartley-Brown MA, Mo CC, Nadeem O et al (2024) Mezigdomide\u2014a novel cereblon E3 ligase modulator under investigation in relapsed\/refractory multiple myeloma. Cancers 16(6):1166","journal-title":"Cancers"},{"issue":"9","key":"7302_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M et al (2025) EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22(9):680\u2013700","journal-title":"Nat Rev Clin Oncol"},{"key":"7302_CR14","unstructured":"Kort\u00fcm M, Auner H, Bassermann F et al Multiples Myelom [Internet]. Onkopedia. [cited 2026 Apr 7]. Available from: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiples-myelom"},{"issue":"8","key":"7302_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H et al (2018) Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 36(8):728\u2013734","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"7302_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","volume":"19","author":"RZ Orlowski","year":"2019","unstructured":"Orlowski RZ, Moreau P, Niesvizky R et al (2019) Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk 19(8):522\u2013530e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"7302_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337","journal-title":"Lancet Oncol"},{"issue":"10245","key":"7302_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos M-V et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396(10245):186\u2013197","journal-title":"Lancet"},{"issue":"1","key":"7302_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos M-V et al (2022) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 23(1):65\u201376","journal-title":"Lancet Oncol"},{"issue":"14","key":"7302_CR20","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos M-V et al (2023) Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv 7(14):3739\u20133748","journal-title":"Blood Adv"},{"key":"7302_CR21","doi-asserted-by":"publisher","unstructured":"Engelhardt M, Ihorst G, Singh M et al (2020) Real-world evaluation of health-related quality of life in patients with multiple myeloma From Germany. Clin Lymphoma Myeloma Leuk 21(2):e160\u2013e175. https:\/\/doi.org\/10.1016\/j.clml.2020.10.002","DOI":"10.1016\/j.clml.2020.10.002"},{"issue":"2","key":"7302_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clml.2019.09.618","volume":"20","author":"H Mian","year":"2020","unstructured":"Mian H, Fiala M, Wildes TM (2020) Adherence to lenalidomide in older adults with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 20(2):98\u2013104e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"7302_CR23","doi-asserted-by":"publisher","first-page":"e0214446","DOI":"10.1371\/journal.pone.0214446","volume":"14","author":"A Cransac","year":"2019","unstructured":"Cransac A, Aho S, Chretien M-L et al (2019) Adherence to immunomodulatory drugs in patients with multiple myeloma. PLoS ONE 14(3):e0214446","journal-title":"PLoS ONE"},{"issue":"1","key":"7302_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1078155220980807","volume":"28","author":"F Santoleri","year":"2022","unstructured":"Santoleri F, Lasala R, Ranucci E et al (2022) Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting. J Oncol Pharm Pract 28(1):24\u201330","journal-title":"J Oncol Pharm Pract"},{"key":"7302_CR25","doi-asserted-by":"publisher","unstructured":"Knauf W, Uhlig J, Heyde E, von der et al (2024) Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed\/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study. Leuk Lymphoma 66(4):691\u2013701. https:\/\/doi.org\/10.1080\/10428194.2024.2436034","DOI":"10.1080\/10428194.2024.2436034"},{"issue":"8","key":"7302_CR26","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"1","key":"7302_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3111\/200710027039","volume":"10","author":"A Sureda","year":"2007","unstructured":"Sureda A, Isla D, C\u00f3zar JM et al (2007) Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. J Med Econ 10(1):27\u201339","journal-title":"J Med Econ"},{"key":"7302_CR28","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) - CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf [Internet]. [cited 2017 Sept 20]. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"issue":"282","key":"7302_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"7302_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","volume":"97","author":"AE Hall","year":"2016","unstructured":"Hall AE, Paul C, Bryant J et al (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 97:247\u2013262","journal-title":"Crit Rev Oncol Hematol"},{"key":"7302_CR31","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1016\/j.jval.2020.08.148","volume":"23","author":"Z Kocaata","year":"2020","unstructured":"Kocaata Z, M\u00fcller S, Maywald U et al (2020) PCN11 non-adherence to oral treatments in patients with multiple myeloma: real-world evidence from a german claims data. Value Health 23:S422","journal-title":"Value Health"},{"issue":"3","key":"7302_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","volume":"18","author":"S Gupta","year":"2018","unstructured":"Gupta S, Abouzaid S, Liebert R et al (2018) Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 18(3):210\u2013218","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"7302_CR33","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00277-021-04543-7","volume":"100","author":"M Solano","year":"2021","unstructured":"Solano M, Daguindau E, Faure C et al (2021) Oral therapy adherence and satisfaction in patients with multiple myeloma. Ann Hematol 100(7):1803\u20131813","journal-title":"Ann Hematol"},{"issue":"3","key":"7302_CR34","first-page":"227","volume":"22","author":"BS Seal","year":"2016","unstructured":"Seal BS, Anderson S, Shermock KM (2016) Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Spec Pharm 22(3):227\u2013235","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"7302_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152","journal-title":"N Engl J Med"},{"issue":"1","key":"7302_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338","journal-title":"Lancet Oncol"},{"issue":"5","key":"7302_CR37","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm A-S, Dold SM et al (2017) A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910\u2013921","journal-title":"Haematologica"},{"issue":"11","key":"7302_CR38","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1016\/j.clml.2025.05.001","volume":"25","author":"H Quach","year":"2025","unstructured":"Quach H, Kim K, Wong RSM et al (2025) Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed\/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study. Clin Lymphoma Myeloma Leuk 25(11):e886\u2013e898","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"7302_CR39","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.3390\/cancers14215311","volume":"14","author":"E Terpos","year":"2022","unstructured":"Terpos E, Zambello R, Leleu X et al (2022) Real-world use and effectiveness of carfilzomib plus dexamethasone in relapsed\/refractory multiple myeloma in Europe. Cancers 14(21):5311","journal-title":"Cancers"},{"key":"7302_CR40","doi-asserted-by":"publisher","first-page":"204062072211045","DOI":"10.1177\/20406207221104584","volume":"13","author":"Y Onda","year":"2022","unstructured":"Onda Y, Kanda J, Kaneko H et al (2022) Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol 13:20406207221104584","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"7302_CR41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clml.2025.08.002","volume":"26","author":"C Hulin","year":"2026","unstructured":"Hulin C, Belhadj Merzoug K, Royer B et al (2026) Real-world utilization of carfilzomib (once or twice weekly) initiated in patients after a first relapse between 2017 and 2022 in France: an analysis from a large-scale epidemiology of multiple myeloma (EmmY) cohort. Clin Lymphoma Myeloma Leuk 26(1):e1\u2013e11e4","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7302_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14193","author":"D Dima","year":"2024","unstructured":"Dima D, Mansour R, Davis JA et al (2024) Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-na\u00efve relapsed multiple myeloma. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.14193","journal-title":"Eur J Haematol"},{"key":"7302_CR43","doi-asserted-by":"publisher","unstructured":"Conticello C, Fabro VD, Romano A et al (2025) Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy. https:\/\/doi.org\/10.1007\/s00277-025-06602-9. [cited 2025 Oct 28]","DOI":"10.1007\/s00277-025-06602-9"},{"issue":"1","key":"7302_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2820","volume":"39","author":"S Rocchi","year":"2021","unstructured":"Rocchi S, Tacchetti P, Pantani L et al (2021) A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma. Hematol Oncol 39(1):41\u201350","journal-title":"Hematol Oncol"},{"issue":"1","key":"7302_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jha2.595","volume":"4","author":"X Leleu","year":"2022","unstructured":"Leleu X, Katodritou E, Kuehr T et al (2022) Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel. EJHaem 4(1):174\u2013183","journal-title":"EJHaem"},{"issue":"2","key":"7302_CR46","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-025-06240-1","volume":"104","author":"A Garcia-Gui\u00f1on","year":"2025","unstructured":"Garcia-Gui\u00f1on A, Charry PA, Jimenez M et al (2025) real-world evidence of carfilzomib, lenalidomide and dexamethasone (KRD) scheme in patients with relapsed \/ refractory multiple myeloma. Ann Hematol 104(2):1177\u20131186","journal-title":"Ann Hematol"},{"issue":"1","key":"7302_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jha2.828","volume":"5","author":"K Laribi","year":"2024","unstructured":"Laribi K, Leleu X, Texier N et al (2024) Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study. EJHaem 5(1):55\u201360","journal-title":"EJHaem"},{"issue":"18","key":"7302_CR48","doi-asserted-by":"publisher","first-page":"16279","DOI":"10.1007\/s00432-023-05385-8","volume":"149","author":"S-S Park","year":"2023","unstructured":"Park S-S, Goo S-Y, Jeon Y-W et al (2023) Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and\/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203). J Cancer Res Clin Oncol 149(18):16279\u201316291","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"7302_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/ejh.13819","volume":"109","author":"ML Del Giudice","year":"2022","unstructured":"Del Giudice ML, Gozzetti A, Antonioli E et al (2022) Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study. Eur J Haematol 109(4):373\u2013380","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07302-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:13Z","timestamp":1791576193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07302-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7302"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07302-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Ammon, c. Losem, J. Hanselmann, S. Koszinowski, (A) Nusch, K. Potthoff, H. Schulz, L. Serrer, (B) Sch\u00f6ttker, (C) Vannier, S. Wilop and S.M. Woerner declare no conflict of interest concerning the topic of this publication.W. Knauf has received consulting fees from iOMEDICO, honoraria for lectures from Amgen, BMS, Johnson & Johnson, Lilly and Sanofi, and support for meetings and\/or travel from Johnson & Johnson.E. von der Heyde has received honoraria from BMS, Novartis, AstraZeneca, iOMEDICO and BeiGene, and has a consulting role for AstraZeneca and Novartis.J. Janssen has received honoraria from Ipsen, Novartis, BMS, Bayer and AstraZeneca, and has received support for meetings and\/or travel from Ipsen, Novartis and Octapharm.M. Welslau has received consulting fees from AstraZeneca, Novartis, Stemline, BMS, Pfizer, Streamed up and Johnson & Johnson, honoraria from AstraZeneca, and has a consulting role for Stemline and GSK.M. Engelhardt has received honoraria from Amgen, BMS, GSK, Johnson & Johnson, OncoXpertise, Pfizer, Sanofi, Sandoz and Takeda, and support for meetings and\/or travel from Johnson & Johnson, Amgen, Sanofi and GSK.J. Uhlig has a consulting role for Roche, Amgen, Servier, MSD, Bristol-Myers Squibb, Sanofi, Merck, Celgene, Novartis, Janssen-Cilag, Boehringer-Ingelheim, Bayer and BeiGene.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used Langdock (a model-agnostic AI platform, Langdock GmbH, Berlin, Germany) The model was used to edit and polish English for clarity and scientific tone. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"448"}}